The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF
Open accessAbstract
OBJECTIVES The goal of this study was to evaluate the effect of empagliflozin, in addition to optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis, and aortic stiffness in nondiabetic patients with heart failure with reduced ejection fraction (HFrEF). BACKGROUND Several randomized clinical trials have established the benefits of the inhibitors of the sodium-glucose cotransporter-2 receptor (SGLT2-i) in HFrEF, independent of their hypoglycemic effects. The mechanisms of the benefits of SGLT2-i in HFrEF have not been well defined. METHODS This study was a secondary analysis of patients enrolled in the EMPA-TROPISM [ATRU-4] (Are the cardiac benefits of Empagliflozin independent of its hypoglycemic activity?) clinical trial. It was a double-blind, placebo-controlled randomized clinical trial investigating the effect of empagliflozin in nondiabetic patients with HFrEF. Patients underwent cardiac magnetic resonance at baseline and after 6 months. Interstitial myocardial fibrosis was calculated by using T1 mapping (extracellular volume). Aortic stiffness was calculated by using pulsed wave velocity, and EAT was measured from the cine sequences. RESULTS Empagliflozin is associated with significant reductions in EAT volume (-5.14 mL; 95% CI: -8.36 to -1.92) compared with placebo (-0.75 mL; 95% CI: -3.57 to 2.06; P < 0.05); this finding was paralleled by reductions in subcutaneous adipose tissue area (-5.33 cm2 [95% CI: -12.61 to 1.95] vs 9.13 cm2 [95% CI: -2.72 to 20.99]; P < 0.05). Empagliflozin-treated patients reported a reduction in extracellular volume (-1.25% [±0.56 95% CI] vs 0.24% [±0.57 95% CI]; (P < 0.01)]; specifically, empagliflozin reduced both matrix volume (-7.24 mL [95% CI: -11.59 to -2.91] vs 0.70 mL [95% CI: -0.89 to 2.29]; P < 0.001) and cardiomyocyte volume (-11.08 mL [95% CI: -19.62 to -2.55] vs 0.80 mL [95% CI: -1.96 to 3.55]; P < 0.05). Pulsed wave velocity was also significantly reduced in the empagliflozin group (-0.58 cm/s [95% CI: -0.92 to -0.25] vs 0.60 cm/s [95% CI: 0.14 to 1.06]; P < 0.01). Using proteomics, empagliflozin was associated with a significant reduction in inflammatory biomarkers. CONCLUSIONS Empagliflozin significantly improved adiposity, interstitial myocardial fibrosis, aortic stiffness, and inflammatory markers in nondiabetic patients with HFrEF. These results shed new light on the mechanisms of action of the benefits of SGLT2-i. (Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity [ATRU-4] [EMPA-TROPISM]; NCT03485222).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Moon, J. C., Messroghli, D. R., Kellman, P., Piechnik, S. K., Robson, M. D., Ugander, M., Gatehouse, P. D., Arai, A. E., Friedrich, M. G., Neubauer, S., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-92 · Cited by 1,136
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Packer, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Self-citationSantos-Gallego, C. G., Vargas-Delgado, A. P., Requena-Ibanez, J. A., Garcia-Ropero, A., Mancini, D., Pinney, S., Macaluso, F., Sartori, S., Roque, M., Sabatel-Perez, F., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.008 · Cited by 531
Self-citationXu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis
Treibel, T. A., Kozor, R., Schofield, R., Benedetti, G., Fontana, M., Bhuva, A. N., Sheikh, A., López, B., González, A., Manisty, C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.035 · Cited by 384
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., Sato, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0658-8 · Cited by 378
Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction
Ho, J. E., Lyass, A., Lee, D. S., Vasan, R. S., Kannel, W. B., Larson, M. G., & Levy, D. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.972828 · Cited by 343
Myocardial Tissue Characterization and Fibrosis by Imaging
Karamitsos, T. D., Arvanitaki, A., Karvounis, H., Neubauer, S., & Ferreira, V. M. (2020) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2019.06.030 · Cited by 228
Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease
Yurista, S. R., Chong, C.-R., Badimon, J. J., Kelly, D. P., de Boer, R. A., & Westenbrink, B. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.065 · Cited by 226
Self-citationGreulich, S., Maxhera, B., Vandenplas, G., de Wiza, D. H., Smiris, K., Mueller, H., Heinrichs, J., Blumensatt, M., Cuvelier, C., Akhyari, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.039586 · Cited by 210
Adiposity and Incident Heart Failure and its Subtypes
Rao, V. N., Zhao, D., Allison, M. A., Guallar, E., Sharma, K., Criqui, M. H., Cushman, M., Blumenthal, R. S., & Michos, E. D. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.07.009 · Cited by 202
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Garcia-Ropero, A., Ishikawa, K., Watanabe, S., Picatoste, B., Vargas-Delgado, A. P., Flores-Umanzor, E. J., Sanz, J., et al. (2021) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2020.07.042 · Cited by 196
Self-citationEpicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk
Villasante Fricke, A. C., & Iacobellis, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235989 · Cited by 184
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
Yagi, S., Hirata, Y., Ise, T., Kusunose, K., Yamada, H., Fukuda, D., Salim, H. M., Maimaituxun, G., Nishio, S., Takagawa, Y., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0275-4 · Cited by 179
Review of MRI-based measurements of pulse wave velocity: a biomarker of arterial stiffness.
Wentland, A. L., Grist, T. M., & Wieben, O. E. (2014) · PubMed · doi:10.3978/j.issn.2223-3652.2014.03.04 · Cited by 166
Regional Adiposity and Heart Failure with Preserved Ejection Fraction
Rao, V. N., Fudim, M., Mentz, R. J., Michos, E. D., & Felker, G. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1956 · Cited by 136
Yang, E. Y., Ghosn, M. G., Khan, M. A., Gramze, N. L., Brunner, G., Nabi, F., Nambi, V., Nagueh, S. F., Nguyen, D. T., Graviss, E. A., et al. (2019) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.119.009535 · Cited by 107
Mason, T., Coelho‐Filho, O. R., Verma, S., Chowdhury, B., Zuo, F., Quan, A., Thorpe, K. E., Bonneau, C., Teoh, H., Gilbert, R. E., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.10.017 · Cited by 105
Parisi, V., Rengo, G., Filardi, P. P., Pagano, G., Femminella, G. D., Paolillo, S., Petraglia, L., Gambino, G., Caruso, A., Grimaldi, M. G., et al. (2016) · Circulation Research · doi:10.1161/circresaha.115.307765 · Cited by 101
Hiruma, S., Shigiyama, F., Hisatake, S., Mizumura, S., Shiraga, N., Hori, M., Ikeda, T., Hirose, T., & Kumashiro, N. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01228-3 · Cited by 81
Santos‐Gallego, C. G., García‐Ropero, Á., MANCINI, D. M., Pinney, S., Contreras, J., Fergus, I. V., Abascal, V. M., Moreno, P., Atallah-Lajam, F., Tamler, R., et al. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-06850-0 · Cited by 67
Self-citation21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient
Neeland, I. J., Yokoo, T., Leinhard, O. D., & Lavie, C. J. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.02.031 · Cited by 60
Hsu, J., Wang, C., Su, M.-Y. M., Lin, L., & Yang, W. (2019) · Scientific Reports · doi:10.1038/s41598-019-51949-5 · Cited by 57
Braha, A., Timar, B., Diaconu, L., Lupușoru, R., Vasiluță, L., Sima, A. C., Vlad, A., Munteanu, M., Albai, A., Cipu, D., et al. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s223629 · Cited by 39
Scully, I. L., McNeil, L. K., Pathirana, S., Singer, C. L., Liu, Y., Mullen, S., Girgenti, D., Gurtman, A., Pride, M. W., Jansen, K. U., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0276-3 · Cited by 35
Parisi, V., Conte, M., Petraglia, L., Grieco, F. V., Bruzzese, D., Caruso, A., Grimaldi, M. G., Campana, P., Gargiulo, P., Paolillo, S., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00043 · Cited by 33
Schneider, F. M., Saulnier, P., Gand, E., Desvergnes, M., Lefort, N., Thorin, É., Thorin‐Trescases, N., Mohammedi, K., Ragot, S., Ricco, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0725-9 · Cited by 20
Shigiyama, F., Hiruma, S., Hisatake, S., Shiraga, N., Ikeda, T., Hirose, T., & Kumashiro, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0640-4 · Cited by 6
Cited by
Epicardial adipose tissue in contemporary cardiology
Iacobellis, G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00679-9 · Cited by 797
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01738-2 · Cited by 93
Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32
Metadata
- Authors
- Requena-Ibáñez, J. A., Santos-Gallego, C. G., Rodriguez-Cordero, A., Vargas-Delgado, A. P., Mancini, D., Sartori, S., Atallah-Lajam, F., Giannarelli, C., Macaluso, F., Lala, A., Sanz, J., Fuster, V., & Badimon, J. J.
- Venue
- JACC: Heart Failure
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 9
- Issue
- 8
- Pages
- 578-589
- ISSN
- 2213-1779 (ISSN-L)
- OpenAlex
- W3186811750
- Cited by
- 264
- References
- 31
- FWCI
- 27.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.